Svetlana Velmar-Janković
![]() | |
![]() | |
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C11H14N2O |
Molar mass | 190.246 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
α-Methylserotonin (αMS), also known as α-methyl-5-hydroxytryptamine (α-methyl-5-HT) or 5-hydroxy-α-methyltryptamine (5-HO-αMT), is a tryptamine derivative closely related to the neurotransmitter serotonin (5-HT). It acts as a non-selective serotonin receptor agonist and has been used extensively in scientific research to study the function of the serotonin system.[1]
Use and effects
According to Alexander Shulgin in TiHKAL, αMS is well-studied in preclinical research but has not been tested in humans.[2]
Pharmacology
αMS is a non-selective and near-full agonist of the serotonin 5-HT2 receptors.[3] It has similar affinity for the 5-HT2A, 5-HT2B, and 5-HT2C receptors.[3] The drug is also a ligand of the serotonin 5-HT1 receptors with high affinity, including of the serotonin 5-HT1A, 5-HT1B, and 5-HT1D receptors (Ki = 40–150 nM), but not of the serotonin 5-HT1E receptor (Ki > 10,000 nM).[1] In addition to its actions at the serotonin receptors, αMS has been found to act as a norepinephrine releasing agent similarly to α-methylphenylalanine and to other α-alkylated tryptamines.[4][5][6]
Unlike serotonin, αMS is not expected to be metabolized by monoamine oxidase on account of the α-methyl substituent blocking the enzyme's access to the amine.[7][8] Similarly to serotonin however, αMS may poorly cross the blood–brain barrier due to its free hydroxyl group, and thus might have weak or no central effects when administered peripherally.[7]
Chemistry
αMS, also known as α-methyl-5-hydroxytryptamine (α-methyl-5-HT), is a substituted tryptamine derivative and the α-methylated analogue of serotonin (5-hydroxytryptamine or 5-HT).
The predicted log P (XLogP3) of αMS is 0.6.[9]
Legal status
United States
αMS is not scheduled at the federal level in the United States,[10] but it could be considered an analogue of α-methyltryptamine (AMT), in which case, purchase, sales, or possession could be prosecuted under the Federal Analog Act.
Florida
αMS is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.[11]
Other drugs
α-Methyltryptophan (αMTP) and α-methyl-5-hydroxytryptophan (α-Me-5-HTP) are prodrugs of αMS which cross the blood–brain barrier and thus efficiently deliver αMS into the central nervous system.[12][13] As a result, these compounds act as orally bioavailable false or substitute neurotransmitters for serotonin, and have been suggested as possible therapeutic agents in the treatment of disorders where serotonin is deficient.[12][13] The O-methylated analogue of αMS, 5-MeO-αMT (α,O-dimethylserotonin; α,O-DMS), also readily enters the brain, and could be used for such purposes as well.[7][14]
See also
References
- ^ a b Ismaiel AM, Titeler M, Miller KJ, Smith TS, Glennon RA (February 1990). "5-HT1 and 5-HT2 binding profiles of the serotonergic agents alpha-methylserotonin and 2-methylserotonin". Journal of Medicinal Chemistry. 33 (2): 755–8. doi:10.1021/jm00164a046. PMID 2299641.
- ^ Alexander T. Shulgin; Ann Shulgin (1997). TiHKAL: The Continuation (1st ed.). Berkeley, CA: Transform Press. ISBN 978-0-9630096-9-2. OCLC 38503252. Retrieved 30 January 2025.
There is some interesting biochemistry and pharmacology all around the edges of α-MT. [...] The 5-hydroxy analogue of α-MT is also a well-studied compound, but not to my knowledge in man. It can be called α-methylserotonin (α-M-5-HT or α-MS), and it is an effective inhibitor of 5-hydroxytryptophan decarboxylase which is the immediate precursor to serotonin (5-HT).
- ^ a b Maroteaux L, Ayme-Dietrich E, Aubertin-Kirch G, Banas S, Quentin E, Lawson R, Monassier L (February 2017). "New therapeutic opportunities for 5-HT2 receptor ligands". Pharmacol Ther. 170: 14–36. doi:10.1016/j.pharmthera.2016.10.008. PMID 27771435.
alpha-methyl-5-HT is a non-selective nearly full agonist at 5-HT2 receptors with similar affinity to 5-HT2A 5-HT2B and 5-HT2C receptors (Jerman, et al., 2001; Knight, et al., 2004; Porter, et al., 1999).
- ^ Lahti RA, Platz PA, Heinzelman RV (July 1969). "Effects of alpha-methyl-5-hydroxytryptophan and alpha-methyl-5-hydroxytryptamine on norepinephrine in mouse myocardium". Biochem Pharmacol. 18 (7): 1601–1608. doi:10.1016/0006-2952(69)90147-6. PMID 5306701.
- ^ Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB (October 2014). "Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes". Psychopharmacology (Berl). 231 (21): 4135–4144. doi:10.1007/s00213-014-3557-7. PMC 4194234. PMID 24800892.
- ^ Blough BE, Landavazo A, Partilla JS, Decker AM, Page KM, Baumann MH, Rothman RB (October 2014). "Alpha-ethyltryptamines as dual dopamine-serotonin releasers". Bioorganic & Medicinal Chemistry Letters. 24 (19): 4754–4758. doi:10.1016/j.bmcl.2014.07.062. PMC 4211607. PMID 25193229.
- ^ a b c "Erowid Online Books : "TIHKAL" - #48 a-MT".
- ^ Diksic M, Nagahiro S, Sourkes TL, Yamamoto YL (January 1990). "A new method to measure brain serotonin synthesis in vivo. I. Theory and basic data for a biological model". Journal of Cerebral Blood Flow and Metabolism. 10 (1): 1–12. doi:10.1038/jcbfm.1990.2. PMID 2298826.
- ^ "3-(2-aminopropyl)-1H-indol-5-ol". PubChem. Retrieved 7 October 2024.
- ^ "§1308.11 Schedule I." Archived from the original on 2009-08-27. Retrieved 2014-12-17.
- ^ Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL
- ^ a b Sourkes TL, Montine TJ, Missala K (1990). "Alpha-methylserotonin, a substitute transmitter for serotonergic neurons". Progress in Neuro-psychopharmacology & Biological Psychiatry. 14 (5): 829–32. doi:10.1016/0278-5846(90)90055-l. PMID 1705718. S2CID 25604266.
- ^ a b Sourkes TL (1991). "Alpha-methyltryptophan as a therapeutic agent". Progress in Neuro-psychopharmacology & Biological Psychiatry. 15 (6): 935–8. doi:10.1016/0278-5846(91)90020-2. PMID 1763198. S2CID 31504647.
- ^ "Erowid Online Books : "TIHKAL" - #5. a,O-DMS".